Journal
DRUG DISCOVERY TODAY
Volume 11, Issue 23-24, Pages 1085-1092Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2006.10.004
Keywords
-
Categories
Funding
- MRC [MC_qA137293] Funding Source: UKRI
- Biotechnology and Biological Sciences Research Council [G18886, MET20484, E19354] Funding Source: researchfish
- Medical Research Council [MC_qA137293] Funding Source: researchfish
- Biotechnology and Biological Sciences Research Council [G18886, MET20484, E19354] Funding Source: Medline
Ask authors/readers for more resources
Unlike signalling pathways, metabolic networks are subject to strict stoichiometric constraints. Metabolomics amplifies changes in the proteome, and represents more closely the phenotype of an organism. Recent advances enable the production (and computer-readable encoding as SBML) of metabolic network models reconstructed from genome sequences, as well as experimental measurements of much of the metabolome. There is increasing convergence between the number of human metabolites estimated via genomics (similar to 3000) and the number measured experimentally. It is thus both timely, and now possible, to bring these two approaches together as an integrated (if distributed) whole to help understand the genesis of metabolic biomarkers, the progress of disease, and the modes of action, efficacy, off-target effects and toxicity of pharmaceutical drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available